In addition, since GLP-1RAs rely on promoting insulin secretion to exert their effects, they are not suitable for patients with T1DM or T2DM with complete pancreatic β-cell failure, and cannot replace insulin therapy (Wajchenberg, 2007). Here, INS is linked to type 2 diabetes mellitus.